Outcomes of persistently active neovascular age-related macular degeneration treated with VEGF inhibitors: observational study data

Barthelmes Daniel; Walton Richard; Campain Anna E.; Simpson Judy M.; Arnold Jennifer J.; McAllister Ian L.; Guymer Robyn H.; Hunyor Alex P.; Essex Rohan W.; Morlet Nigel; Gillies Mark C.

首页> 外文期刊>British journal of ophthalmology >Outcomes of persistently active neovascular age-related macular degeneration treated with VEGF inhibitors: observational study data

【24h】

Outcomes of persistently active neovascular age-related macular degeneration treated with VEGF inhibitors: observational study data

机译：VEGF抑制剂治疗持续活跃的新血管性年龄相关性黄斑变性的结果：观察性研究数据

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Aim To describe outcomes of eyes with wet age-related macular degeneration (AMD) subdivided by lesion activity in a large multicentre cohort study.

机译：目的在大型多中心队列研究中描述湿性年龄相关性黄斑变性（AMD）的眼结局（按病变活动细分）。

著录项

来源
《British journal of ophthalmology》 |2015年第3期|共6页
作者
Barthelmes Daniel; Walton Richard; Campain Anna E.; Simpson Judy M.; Arnold Jennifer J.; McAllister Ian L.; Guymer Robyn H.; Hunyor Alex P.; Essex Rohan W.; Morlet Nigel; Gillies Mark C.;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类眼科学;
关键词

相似文献

外文文献
中文文献
专利

1. Outcomes of persistently active neovascular age-related macular degeneration treated with VEGF inhibitors: observational study data [J] . Barthelmes Daniel, Walton Richard, Campain Anna E., British journal of ophthalmology . 2015,第3期

机译：VEGF抑制剂治疗持续活跃的新血管性年龄相关性黄斑变性的结果：观察性研究数据
2. Two years outcomes in eyes receiving aflibercept according to fixed 2 month interval for neovascular age-related macular degeneration: observational study dataTwo years outcomes in eyes receiving aflibercept according to fixed 2 month interval for neovascular age-related macular degeneration: observational study data [J] . Kanda Koji, Sato Tomohito, Taguchi Manzo, Investigative ophthalmology & visual science . 2017,第8期

机译：根据固定的2个月间隔接受AfliBercept的眼睛两年的结果与新生血管年龄相关的黄斑变性：观察研究DataTwo岁月后的眼睛，接受AfliBercept的目的，根据固定的2个月的新生血管年龄相关性黄斑变性：观察研究数据
3. Pilot study to evaLuate the role of high-dose rAnibizumab 2.0 mg in the management of neovascular age-related macular degeneration in patients with perSistent/recurrenT macular fluid <30 days following treatment with intravitreal anti-VEGF therapy (the LAST Study) [J] . FungA.T., KumarN., VanceS.K., Eye . 2012,第9期

机译：在玻璃体内注射抗VEGF治疗后持续/复发性黄斑积液<30天的患者中评估大剂量rAnibizumab 2.0 mg在管理新生血管性年龄相关性黄斑变性中的作用的试验研究（LAST研究）
4. Bevacizumab (Avastin) conjugated microbubbles for anti-VEGF treatment of neovascular age-related macular degeneration [C] . Leilei Zhang, Jeff Xu, Jiwei Huang, Conference on ophthalmic technologies . 2010

机译：贝伐单抗（Avastin）缀合的微泡用于抗VEGF治疗新生血管性年龄相关性黄斑变性
5. Macular atrophy findings by optical coherence tomography angiography compared with fundus autofluorescence in treated exudative age-related macular degeneration [D] . 高砂縁 2019

机译：光学相干断层扫描血管造影与眼底自发荧光相比黄斑萎缩在治疗渗出性年龄相关性黄斑变性中的作用
6. Pilot study to evaLuate the role of high-dose rAnibizumab 2.0 mg in the management of neovascular age-related macular degeneration in patients with perSistent/recurrenT macular fluid 30 days following treatment with intravitreal anti-VEGF therapy (the LAST Study) [O] . A T Fung, N Kumar, S K Vance, 2012

机译：评价玻璃体腔内抗VEGF治疗后持续/复发黄斑积液30天的患者中大剂量rAnibizumab2.0μmg在新生血管性黄斑变性管理中的作用的初步研究（LAST研究）
7. Pilot study to evaLuate the role of high-dose rAnibizumab 2.0 mg in the management of neovascular age-related macular degeneration in patients with perSistent/recurrenT macular fluid <30 days following treatment with intravitreal anti-VEGF therapy (the LAST Study) [O] . A T Fung, N Kumar, S K Vance, 2012

机译：试点研究评估高剂量ranibizumab 2.0mg在持续/复发性黄斑液患者患者的新血管年龄相关性黄斑运动中的作用<30天后玻璃体抗VEGF治疗（最后一项研究）

Outcomes of persistently active neovascular age-related macular degeneration treated with VEGF inhibitors: observational study data

摘要

著录项

相似文献

相关主题

期刊订阅